[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100274403":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":25,"studyPopulation":11,"armGroups":26,"interventions":39,"overallOfficials":51,"centralContacts":56,"locations":64,"responsibleParty":81,"collaborators":11,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":11,"eligibilityCriteria":91,"healthyVolunteers":87,"sex":92,"minAge":11,"maxAge":11,"enrollmentInfo":93,"targetDuration":11,"studyType":96,"phases":97,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":66,"whyStopped":11,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Chinese PLA General Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":16},[9],{"measure":10,"description":11,"timeFrame":12},"Cumulative survival rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test.",null,"up to 8 years",[14],{"measure":15,"description":11,"timeFrame":12},"disease free survival rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test",[17],{"measure":18,"description":11,"timeFrame":12},"Local tumor progress rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test",{"allocation":20,"interventionModel":21,"interventionModelDescription":11,"primaryPurpose":22,"observationalModel":11,"timePerspective":11,"maskingInfo":23},"NON_RANDOMIZED","PARALLEL","TREATMENT",{"masking":24,"maskingDescription":11,"whoMasked":11},"NONE","Patients with HCC (tumor diameter ≤5 cm and fewer than three tumors) underwent radical MWA followed by cellular immunotherapy. In the CIK-based cohort, patients received 4-6 courses annually, starting at 2, 4, 6, 10, 14, and 18 weeks after MWA, followed by treatment every 12 weeks. Peripheral blood mononuclear cells were differentiated into phenotypically confirmed DCs and effector cells. DC-CIK and CTL were administered intraperitoneally, and CIK cells were infused intravenously.\n\nIn the NK-cell cohort, patients received six NK-cell infusions at 2-week intervals after complete MWA and normalization of body temperature. NK cells were expanded ex vivo from autologous peripheral blood, allogeneic peripheral blood, or umbilical cord blood.",[27,33],{"label":28,"type":29,"description":30,"interventionNames":31},"MWA only","ACTIVE_COMPARATOR","The HCC patients will be treated only by MWA.No adoptive immunotherapy will be used.",[32],"Procedure: MWA",{"label":34,"type":35,"description":36,"interventionNames":37},"MWA combined with immunotherapy","EXPERIMENTAL","The HCC patients will be treated firstly by MWA, and then treated by courses of adoptive immunotherapy.",[38,32],"Biological: adoptive immunotherapy",[40,46],{"type":41,"name":42,"description":25,"armGroupLabels":43,"otherNames":44},"BIOLOGICAL","adoptive immunotherapy",[34],[45],"cytokine induced kill cell",{"type":47,"name":48,"description":49,"armGroupLabels":50,"otherNames":11},"PROCEDURE","MWA","ALL the HCC patients will be treated only by microwave ablation and then enter the follow-up",[34,28],[52],{"name":53,"affiliation":54,"role":55},"Ping Liang, Dr.","Chinese PLA General Hospial","STUDY_DIRECTOR",[57,62],{"name":58,"role":59,"phone":60,"phoneExt":11,"email":61},"Jie Yu, Dr.","CONTACT","8610-66939530","yu-jie301@hotmail.com",{"name":63,"role":59,"phone":60,"phoneExt":11,"email":11},"Mengjuan Mu, Ms.",[65],{"facility":5,"status":66,"city":67,"state":68,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":78},"RECRUITING","Beijing","Beijing Municipality","100853","China","CN",{"type":73,"coordinates":74},"Point",[75,76],116.39723,39.9075,{"lat":76,"lon":75},[79],{"name":80,"role":59,"phone":60,"phoneExt":11,"email":61},"Jie Yu, Doctor",{"type":82,"investigatorFullName":83,"investigatorTitle":84,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Ping Liang","Professor","100274403","phase-2-combination-therapy-of-microwave-ablation-and-cellular-immunotherapy-for-hepatocellular-carcinoma-100274403",false,"NCT02851784","Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma","Combination Therapy of Microwave Ablation and Expanding Activated Autologous Lymphocytes for Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. single HCC of 5 cm or smaller;\n2. three or fewer multiple HCC with a maximum dimension of 3 cm or less;\n3. absence of portal vein thrombosis or extrahepatic metastases;\n4. Child-Pugh classification A or B;\n5. tumor accessible via a percutaneous approach. white blood cell count \\>2 x 109\u002FL, platelet count \\>40 x 109\u002FL,serum creatinine \\\u003C110 μmol\u002FL, aspartate aminotransferase \\\u003C3 times the upper limit, serum bilirubin \\\u003C2.5 times the upper limit, prothrombin time \\\u003C19 seconds.\n\nExclusion Criteria:\n\n1. pregnant or breast-feeding; psychiatric problems, addiction, or any other disorder that prevented informed consent;\n2. active uncontrolled infection; concurrent systemic corticosteroid treatment;\n3. systemic autoimmune disease;\n4. clinically significant ischemic heart disease or cardiac failure;\n5. and chemotherapy or radiotherapy within the preceding 6 months","ALL",{"count":94,"type":95},80,"ESTIMATED","INTERVENTIONAL",[98,99],"PHASE2","PHASE3","The study is to observe safety, survival effect and peripheral T-lymphocyte subsets of combination therapy with percutaneous microwave ablation (MWA) and adoptive immunotherapy in hepatocellular carcinoma(HCC).",[102],"Hepatocellular Carcinoma",[104,105,106,45],"hepatocellular carcinoma","ablation","immunotherapy","2026-09-15",{"date":109,"type":110},"2026-09-17","ACTUAL",{"date":112,"type":110},"2009-12",{"date":114,"type":95},"2028-12-31",{"name":5,"class":6},1]